Morgan Stanley analyst Erik Woodring maintains Vivint Smart Home (NYSE:VVNT) with a Equal-Weight and raises the price target from $13 to $14.
Alaunos Therapeutics Highlights Data From TCR-T Library Phase 1/2 Trial At The CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference; Data To Be Presented On Friday, September 30
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post infusion
Sleeping Beauty TCR-T cell therapy had a manageable safety
